MYndspan

MYndspan operates at the intersection of neuroscience, diagnostics, personal health, and clinical research. Its differentiation is the consumer-facing use of clinical-grade magnetoencephalography rather than relying solely on consumer wearables or subjective cognitive assessments. The company combines a 45-minute MEG scan with cognitive testing, then produces a brain-function report intended to establish a baseline and support longitudinal monitoring. Its stated analytical foundation includes more than 300 peer-reviewed MEG studies and over 2,000 research-grade MEG datasets. Partnerships with EMOTIV, BIOS Health, IMEDCO, and MEGIN broaden the proposition across EEG, health-data infrastructure, scanning equipment, and consumer access. This gives MYndspan a potentially distinctive position between specialist neuroimaging providers and consumer wellness platforms. The company remains a small private business with an employee range of one to ten and $348,749 in disclosed funding, suggesting an early commercial stage rather than an established category leader.

MYndspan’s trajectory shows a progression from company formation in 2020 toward a consumer-accessible brain-health platform. Two undisclosed funding rounds were recorded in January and September 2021, followed by a strategic corporate round involving Emotiv on Apr 10, 2025 and a $348,749 equity crowdfunding round announced on May 8, 2025. The 2025 partnership sequence was an important inflection point: BIOS Health was added in February, Emotiv in April, and IMEDCO later that month. Together, these relationships address data, EEG, MEG hardware, and delivery infrastructure rather than representing isolated promotional activity. The product set currently centers on the MYndspan Baseline Brain Assessment and MYndspan Brain Function Report, indicating an assessment-and-monitoring model. The January 2026 sleep-quality announcement further demonstrated use of MEG for dynamic brain-function analysis and extended the narrative beyond one-time testing.